Nanostructured SBA-15 silica: An effective protective vehicle to oral hepatitis B vaccine immunization

Author(s):Show less -

Scaramuzzi, Karina ; Tanaka, Gabriela D. ; Mariano Neto, Francisco ; Garcia, Paulo R. A. F. ; Gabrili, Joel J. M. ; Oliveira, Denise C. A. ; Tambourgi, Denise V. ; Mussalem, Juliana S. ; Paixao-Cavalcante, Danielle ; D'Azeredo Orlando, Marcos T. ; Botosso, Viviane F. ; Oliveira, Cristiano L. P. ; Fantini, Marcia C. A. ; Sant'Anna, Osvaldo A.

• Document type: Journal article
• Source: Nanomedicine-Nanotechnology Biology and Medicine; v. 12, n. 8, p. 2241-2250, NOV 2016.
• Web of Science Citations: 4

Abstract

Due to its physicochemical properties, nanostructured mesoporous SBA-15 silica shows great potential as a vaccine adjuvant. This study evaluated the capacity of SBA-15 to encapsulate/adsorb the recombinant purified HBsAg from the Hepatitis B virus and the immunoresponsiveness of mice orally immunized with HBsAg inside SBA-15. A simulation of small angle X-ray scattering experimental results, together with the nitrogen adsorption isotherms data, allowed to determine the appropriate mass ratio of HBsAg: SBA-15, indicating antigen encapsulation into SBA-15 macroporosity. This was also evaluated by bicinchoninic acid assay and gel electrophoresis. The recruitment of inflammatory cells, an increase in production of specific antibodies, and the non-influence of silica on TH1 or TH2 polarization were observed after oral immunization. Besides, SBA-15 enhanced the phagocytosis of ovalbumin by dendritic cells, an important key to prove how this adjuvant works. Thus, it seems clear that the nanostructured SBA-15 is an effective and safe adjuvant for oral immunizations. (C) 2016 Elsevier Inc. All rights reserved. (AU)

• FAPESP's process: 13/07467-1 - CeTICS - Center of Toxins, Immune-Response and Cell Signaling
• Grantee: Hugo Aguirre Armelin
• Support Opportunities: Research Grants - Research, Innovation and Dissemination Centers - RIDC